Archives of Gynecology and Obstetrics

, Volume 283, Issue 1, pp 7–18

Antibiotic chemotherapy during pregnancy and lactation period: aspects for consideration

Materno-fetal Medicine

Abstract

Background

Infections during gestation, delivery and the postnatal period can jeopardise not only the mother, but also the child. Along with chromosomal abnormalities and immunological diseases, infection in early pregnancy represents the most important reason for abortion. During the second and third trimester, infections are the principal cause for preterm labour, premature membrane rupture, premature delivery and the resultant complications in the newborn child. Many pregnant women are very cautious about taking antibiotics due to primarily potentially detrimental effects on the unborn child. However, there are no contraindications for antibiotic treatment during pregnancy in the event of a serious infectious disease of the mother.

Materials and methods

In this review the indications and contraindications of the administration of antibiotics during pregnancy are being reviewed.

Results

Penicillins are a first-line antibiotic treatment during pregnancy, with the exception of cases in which there is a maternal allergy to penicillin. Cephalosporins are another first-line antibiotic used during pregnancy. In principle, more commonly used cephalosporins should be given priority. Owing to associated nephrotoxicity and ototoxicity, aminoglycosides should not be prescribed at any time during pregnancy. Systematic use of aminoglycosides should be considered solely in the event of life-threatening infections with gram-negative pathogens and/or treatment failure of recommended antibiotics during pregnancy. The use of metronidazole is also permitted during pregnancy, provided the indications for its use have been strictly verified. Lincosamides should be used only if penicillins, cephalosporins and erythromycin have failed to eradicate infection. Sulfonamides, trimethoprim and cotrimoxazole are second-line agents for the use during pregnancy. Tetracyclines should not be administered to pregnant women after the fifth week of pregnancy, and are deemed contraindicated. As a precautionary measure, gyrase inhibitors are also contraindicated for pregnant women, children and young adolescents.

Conclusion

On the basis of our current state of knowledge, the vast majority of antibiotics do not cause serious harm to the unborn child if used properly and at the appropriate doses during pregnancy. The treatment with an antibiotic that is contraindicated does not justify termination of pregnancy. However, ultimately no medicine, including antibiotics, can be described as absolutely safe.

Keywords

Pregnancy Antibiotics Treatment Contraindication Adverse outcome 

References

  1. 1.
    Mylonas I, Dian D, Friese K (2005) Antibiotikatherapie in der Schwangerschaft. Gynakologe 38:761–770CrossRefGoogle Scholar
  2. 2.
    Mylonas I, Friese K (2009) Infektionen in der Gynäkologien und Geburtshilfe. Elsevier Verlag/Urban & Fischer, MünchenGoogle Scholar
  3. 3.
    Friese K, Schäfer A, Hof H (2002) Infektionen in der Gynäkologie und Geburtshilfe. Springer, BerlinGoogle Scholar
  4. 4.
    Friese K, Mörike K, Neumann G, Windorfer A (2009) Arzneimittel in der Schwangerschaft und Stillzeit: Ein Leitfaden für Ärzte und Apotheker Wissenschaftliche Verlagsgesellschaft mbH, StuttgartGoogle Scholar
  5. 5.
    Friese K, Melchert F (2002) Arzneimitteltherapie in der Frauenheilkunde. Wissenschaftliche Verlagsgesellschaft mbH, StuttgartGoogle Scholar
  6. 6.
    Briggs GG, Freeman RK, Yaffe SJ (1998) Drugs in pregnancy and lactation. Williams & Wilkins, BaltimoreGoogle Scholar
  7. 7.
    Saunders EJ, Saunders JA (1990) Drug therapy in pregnancy: the lessons of diethylstilbestrol, thalidomide, and bendectin. Health Care Women Int 11:423–432CrossRefPubMedGoogle Scholar
  8. 8.
    (2001) Erythromycin-induced pyloric stenosis in infants. Prescrire Int 10:16Google Scholar
  9. 9.
    Mahon BE, Rosenman MB, Kleiman MB (2001) Maternal and infant use of erythromycin and other macrolide antibiotics as risk factors for infantile hypertrophic pyloric stenosis. J Pediatr 139:380–384CrossRefPubMedGoogle Scholar
  10. 10.
    Norgaard M, Skriver MV, Sorensen HT, Schonheyder HC, Pedersen L (2008) Risk of miscarriage for pregnant users of pivmecillinam: a population-based case–control study. APMIS 116:278–283PubMedGoogle Scholar
  11. 11.
    Sa del Fiol F, Gerenutti M, Groppo FC (2005) Antibiotics and pregnancy. Pharmazie 60:483–493PubMedGoogle Scholar
  12. 12.
    Amann U, Egen-Lappe V, Strunz-Lehner C, Hasford J (2006) Antibiotics in pregnancy: analysis of potential risks and determinants in a large German statutory sickness fund population. Pharmacoepidemiol Drug Saf 15:327–337CrossRefPubMedGoogle Scholar
  13. 13.
    Bertsche T, Haas M, Oberwittler H, Haefeli WE, Walter-Sack I (2006) Drugs during pregnancy and breastfeeding: new risk categories—antibiotics as a model. Dtsch Med Wochenschr 131:1016–1022CrossRefPubMedGoogle Scholar
  14. 14.
    Nahum GG, Uhl K, Kennedy DL (2006) Antibiotic use in pregnancy and lactation: what is and is not known about teratogenic and toxic risks. Obstet Gynecol 107:1120–1138CrossRefPubMedGoogle Scholar
  15. 15.
    Haas A, Maschmeyer G (2008) Antibiotic therapy in pregnancy. Dtsch Med Wochenschr 133:511–515CrossRefPubMedGoogle Scholar
  16. 16.
    Schäfer C, Spielman H (2001) Arzneimittelverordnung in Schwangerschaft und Stillzeit. Elsevier Urban und Fischer, Berlin, JenaGoogle Scholar
  17. 17.
    Dencker BB, Larsen H, Jensen ES, Schonheyder HC, Nielsen GL, Sorensen HT (2002) Birth outcome of 1886 pregnancies after exposure to phenoxymethylpenicillin in utero. Clin Microbiol Infect 8:196–201CrossRefPubMedGoogle Scholar
  18. 18.
    Lewis DF, Adair CD, Robichaux AG, Jaekle RK, Moore JA, Evans AT, Fontenot MT (2003) Antibiotic therapy in preterm premature rupture of membranes: are seven days necessary? A preliminary, randomized clinical trial. Am J Obstet Gynecol 188:1413–1416 (discussion 1416–1417)CrossRefPubMedGoogle Scholar
  19. 19.
    Czeizel AE, Rockenbauer M, Sorensen HT, Olsen J (2001) Augmentin treatment during pregnancy and the prevalence of congenital abnormalities: a population-based case–control teratologic study. Eur J Obstet Gynecol Reprod Biol 97:188–192CrossRefPubMedGoogle Scholar
  20. 20.
    Sigg TR, Kuhn BR (2000) Inadvertent intrauterine infusion of ampicillin–sulbactam. Am J Health Syst Pharm 57:215PubMedGoogle Scholar
  21. 21.
    Simon C, Stille W (2000) Antibiotika—Therapie in Klinik und Praxis. Schattauer, StuttgartGoogle Scholar
  22. 22.
    Garratty G, Leger RM, Arndt PA (1999) Severe immune hemolytic anemia associated with prophylactic use of cefotetan in obstetric and gynecologic procedures. Am J Obstet Gynecol 181:103–104CrossRefPubMedGoogle Scholar
  23. 23.
    Berkovitch M, Segal-Socher I, Greenberg R, Bulkowshtein M, Arnon J, Merlob P, Or-Noy A (2000) First trimester exposure to cefuroxime: a prospective cohort study. Br J Clin Pharmacol 50:161–165CrossRefPubMedGoogle Scholar
  24. 24.
    Czeizel AE, Rockenbauer M, Sorensen HT, Olsen J (2001) Use of cephalosporins during pregnancy and in the presence of congenital abnormalities: a population-based, case–control study. Am J Obstet Gynecol 184:1289–1296CrossRefPubMedGoogle Scholar
  25. 25.
    Manka W, Solowiow R, Okrzeja D (2000) Assessment of infant development during an 18-month follow-up after treatment of infections in pregnant women with cefuroxime axetil. Drug Saf 22:83–88CrossRefPubMedGoogle Scholar
  26. 26.
    Heikkila A, Erkkola R (1994) Review of β-lactam antibiotics in pregnancy. The need for adjustment of dosage schedules. Clin Pharmacokinet 27:49–62CrossRefPubMedGoogle Scholar
  27. 27.
    Czeizel AE, Rockenbauer M, Sorensen HT, Olsen J (1999) A population-based case-control teratologic study of oral erythromycin treatment during pregnancy. Reprod Toxicol 13:531–536CrossRefPubMedGoogle Scholar
  28. 28.
    Einarson A, Phillips E, Mawji F, D’Alimonte D, Schick B, Addis A, Mastroiacova P, Mazzone T, Matsui D, Koren G (1998) A prospective controlled multicentre study of clarithromycin in pregnancy. Am J Perinatol 15:523–525CrossRefPubMedGoogle Scholar
  29. 29.
    Schick B, Hom M, Librizzi R, Donnenfeld A (1996) Pregnancy outcome following exposure to clarithromycin. Reprod Toxicol 10:162Google Scholar
  30. 30.
    Czeizel AE, Rockenbauer M, Olsen J, Sorensen HT (2000) A case–control teratological study of spiramycin, roxithromycin, oleandomycin and josamycin. Acta Obstet Gynecol Scand 79:234–237CrossRefPubMedGoogle Scholar
  31. 31.
    Kallen BA, Otterblad Olausson P, Danielsson BR (2005) Is erythromycin therapy teratogenic in humans? Reprod Toxicol 20:209–214PubMedGoogle Scholar
  32. 32.
    Schardein JL (2000) Chemically induced birth defects. Marcel Dekker, New YorkGoogle Scholar
  33. 33.
    Lewis JH (1991) Drug hepatotoxicity in pregnancy. Eur J Gastroenterol Hepatol 3:883–891Google Scholar
  34. 34.
    Trexler MF, Fraser TG, Jones MP (1997) Fulminant pseudomembranous colitis caused clindamycin phosphate vaginal cream. Am J Gastroenterol 92:2113Google Scholar
  35. 35.
    Joesoef M, Schmid G (2002) Bacterial vaginosis. Clin Evid 1592–1600Google Scholar
  36. 36.
    Czeizel AE, Rockenbauer M, Olsen J, Sorensen HT (2000) A teratological study of aminoglycoside antibiotic treatment during pregnancy. Scand J Infect Dis 32:309–313CrossRefPubMedGoogle Scholar
  37. 37.
    Freeman CD, Klutman NE, Lamp KC (1997) Metronidazole: a therapeutic review and update. Drugs 54:679–708CrossRefPubMedGoogle Scholar
  38. 38.
    Diav-Citrin O, Gotteiner T, Shechtman S, Arnon J, Ornoy A (2000) Pregnancy outcome following gestational exposure to metronidazole: a prospective controlled cohort study (abstract). Teratology 61:440Google Scholar
  39. 39.
    Thapa PB, Whitlock JA, Brockman Worrell KG, Gideon P, Mitchel EF, Roberson P, Pais R, Ray WA (1998) Prenatal exposure to metronidazole and risk of childhood cancer. Cancer 83:1461–1468CrossRefPubMedGoogle Scholar
  40. 40.
    Beard CM, Noller KL, O’Fallon WM, Kurland LT, Dahlin DC (1988) Cancer after exposure to metronidazole. Mayo Clin Proc 63:147–153PubMedGoogle Scholar
  41. 41.
    Caro-Paton T, Carvajal A, Martin de Diego I, Martin-Arias LH, Alvares-Requejo A, Rodriguez-Pinilla E (1997) Is metronidazole teratogenic? A meta-analysis. Br J Clin Pharmacol 44:179–182CrossRefPubMedGoogle Scholar
  42. 42.
    Czeizel AE, Rockenbauer M (1998) A population based case-control teratologic study of oral metronidazole treatment during pregnancy. Br J Obstet Gynaecol 105:2–7Google Scholar
  43. 43.
    Czeizel AE (1990) A case–control analysis of the teratogenic effects of co-trimoxazole. Reprod Toxicol 4:305–313CrossRefPubMedGoogle Scholar
  44. 44.
    Heinonen OP, Slone D, Shapiro S (1977) Birth defects and drugs in pregnancy. Publishing Sciences Group, LittletonGoogle Scholar
  45. 45.
    Friese K, Hlobil H (1997) Prenatal toxoplasmosis: is screening in pregnancy necessary? Z Geburtshilfe Neonatol 201:115–120PubMedGoogle Scholar
  46. 46.
    Friese K (1994) Diagnosis and treatment of congenital toxoplasmosis. Geburtshilfe Und Frauenheilkunde 54:M99–M101PubMedGoogle Scholar
  47. 47.
    Wenk RE, Gebhardt FC, Bhagavan BS, Lustgarten JA, McCarthy EF (1981) Tetracycline-associated fatty liver of pregnancy, including possible pregnancy risk after chronic dermatologic use of tetracycline. J Reprod Med 26:135–141PubMedGoogle Scholar
  48. 48.
    Whalley PJ, Martin FG, Adams RH, Combes B (1970) Disposition of tetracycline by pregnant women with acute pyelonephritis. Obstet Gynecol 36:821–826PubMedGoogle Scholar
  49. 49.
    Czeizel AE, Rockenbauer M (2000) A population-based case–control study of oral oxytetracycline treatment during pregnancy. Eur J Obstet Gynecol Reprod Biol 88:27–33CrossRefPubMedGoogle Scholar
  50. 50.
    Takayama S, Watanabe T, Akiyama Y, Ohura K, Harada S, Matsuhashi K, Mochida K, Yamashita N (1986) Reproductive toxicity of ofloxacin. Arzneimittelforschung 36:1244–1248PubMedGoogle Scholar
  51. 51.
    Gough AW, Kasali OB, Sigler RE, Baragi V (1992) Quinolone arthropathy acute toxicity to immature articular cartilage. Toxicol Pathol 20:436–449CrossRefPubMedGoogle Scholar
  52. 52.
    Schaefer C, Amoura-Elefant E, Vial T, Ornoy A, Garbis H, Robert E, Rodriguez-Pinilla E, Pexieder T, Prapas N, Merlob P (1996) Pregnancy outcome after prenatal quinolone exposure. Evaluation of a case registry of the European Network of Teratology Information Services (ENTIS). Eur J Obstet Gynecol Reprod Biol 69:83–89CrossRefPubMedGoogle Scholar
  53. 53.
    Berkovitch M, Pastuszak A, Gazarian M, Lewis M, Koren G (1994) Safety of the new quinolones in pregnancy. Obstet Gynecol 84:535–538PubMedGoogle Scholar
  54. 54.
    Loebstein R, Addis A, Ho E, Andreou R et al (1998) Pregnancy outcome following gestational exposure to fluoroquinolones: a multicenter prospective controlled study. Antimicrob Agents Chemother 42:1336–1339PubMedGoogle Scholar
  55. 55.
    Holdiness MR (1987) Teratology of the antituberculosis drugs. Early Hum Dev 15:61–74CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  1. 1.Division of Infectious Diseases in Gynaecology and Obstetrics, 1st Department of Obstetrics and GynaecologyLudwig-Maximilians-University MunichMunichGermany

Personalised recommendations